Last reviewed 2026-04-19 · How we verify

PAZUFLOXACIN

Pazufloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and transcription.

Pazufloxacin is a small molecule antibiotic belonging to the fluoroquinolone class. It is used to treat sepsis caused by Streptococcus pneumoniae. The commercial status of pazufloxacin is unclear, but it is likely patented. Key safety considerations include its potential to cause tendon damage and central nervous system effects. Further research is needed to fully understand its pharmacokinetics and safety profile.

At a glance

Mechanism of action

Imagine your body's cells are like factories that make copies of themselves. Bacteria have their own factories too, and pazufloxacin stops these factories from working by blocking the enzymes that help them make copies of their DNA. This prevents the bacteria from growing and multiplying, ultimately helping to clear the infection.

Approved indications

• Sepsis due to Streptococcus pneumoniae

Common side effects

No common side effects on file.

Key clinical trials

• Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%. (PHASE3)
• Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin) (PHASE2)
• Pazufloxacin Mesilate Ear Drops in Patients With Chronic Suppurative Otitis Media (PHASE1)
• Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• PAZUFLOXACIN CI brief — competitive landscape report
• PAZUFLOXACIN updates RSS · CI watch RSS